[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Hoshimoto S, Morise Z, Takeura C, Ikeda M, Kagawa T, Tanahashi Y, Okabe Y, Mizoguchi Y, Sugioka A: Malignant Triton tumor in the retroperitoneal space associated with neurofibromatosis type 1: a case study. Rare Tumors; 2009;1(2):e27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant Triton tumor in the retroperitoneal space associated with neurofibromatosis type 1: a case study.
  • We report an extremely rare case of malignant Triton tumor developing in the retroperitoneal space in a patient with neurofibromatosis type 1.
  • A 21-year old man who had been diagnosed with neurofibromatosis type 1 was admitted to our hospital with the chief complaint of a palpable abdominal mass.
  • Abdominal computed tomography revealed a huge heterogeneous tumor measuring approximately 17 cm in diameter occupying the left retroperitoneal space, and numerous metastatic lesions between the left psoas muscle and the left thigh with dissolution of the left hip joint.
  • After the diagnosis of a retroperitoneal malignant neurogenic tumor, resection of the tumor with reconstruction of the abdominal aorta was conducted, followed by postoperative transarterial infusion chemotherapy.
  • The histopathological diagnosis was malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation, namely malignant Triton tumor.
  • Postoperative chemotherapy was in vain and the patient died 14 months after the surgery as a result of lung metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139906.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994481
  • [Keywords] NOTNLM ; malignant Triton tumor / malignant peripheral nerve sheath tumor / neurofibromatosis / retroperitoneal tumor.
  •  go-up   go-down


2. Abe T, Yamanaka K, Nakata W, Mori N, Sekii K, Yoshioka T, Itatani H: [A case of retroperitoneal malignant fibrous histiocytoma with marked response to concurrent cisplatin and radiation therapy: a case report]. Hinyokika Kiyo; 2007 Apr;53(4):241-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal malignant fibrous histiocytoma with marked response to concurrent cisplatin and radiation therapy: a case report].
  • Abdominal computed tomography and magnetic resonance imaging revealed a large retroperitoneal tumor adjacent to the aorta and the renal vessels.
  • Then we performed percutaneous needle biopsy of the tumor.
  • Histopathological examination showed a malignant fibrous histiocytoma (MFH).
  • Two cycles of systemic chemotherapy with pirarubicin, vincritine and cyclophosphamide were ineffective, then we tried concurrent cisplatin and radiation therapy.
  • Chemoradiation therapy showed a marked decrease in the size of the tumor, and the patient also recovered from right lumbar pain without serious side effects.
  • After chemoradiation therapy, we performed tumorectomy.
  • However, we could not curatively resect the residual tumor.
  • We performed repeatedly concurrent cisplatin and radiation therapy for the recurrent and metastatic tumor sites, and chemoradiation therapy led to regression of the tumors every time.
  • Concurrent cisplatin and radiation therapy might be an effective treatment for unresectable MFH.
  • [MeSH-major] Cisplatin / therapeutic use. Histiocytoma, Malignant Fibrous / drug therapy. Histiocytoma, Malignant Fibrous / radiotherapy. Radiation-Sensitizing Agents / therapeutic use. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515074.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Okumura K, Kato K, Furuhashi K, Suzuki K, Murase T: [A collision cancer between urothelial carcinoma and malignant lymphoma of the urinary bladder: a case report]. Hinyokika Kiyo; 2007 Sep;53(9):649-51
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A collision cancer between urothelial carcinoma and malignant lymphoma of the urinary bladder: a case report].
  • Abdominal computed tomography showed a low-density area in the liver and swelling of lymph nodes surrounding the abdominal aorta.
  • Cystoscopy revealed massive blood clots and a papillary tumor at the left wall of the urinary bladder.
  • He underwent transurethral resection of a bladder tumor, and the pathological diagnosis was a collision tumor between urothelial carcinoma (G2, pTa) and malignant lymphoma (B cell type).
  • He underwent a liver biopsy soon thereafter, and the pathological diagnosis was malignant lymphoma (as for the one found in the urinary bladder).
  • Bladder tamponade was repeated, which was relieved after one course of chemotherapy for malignant lymphoma.
  • He underwent six courses of chemotherapy (THP-CO), and he was well without recurrence of either malignant lymphoma or urothelial carcinoma with 3 years' follow-up.
  • To our knowledge, this is the 14th reported case of a collision tumor in the urinary tract.

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933143.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Clere N, Corre I, Faure S, Guihot AL, Vessières E, Chalopin M, Morel A, Coqueret O, Hein L, Delneste Y, Paris F, Henrion D: Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer; 2010 Nov 15;127(10):2279-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis.
  • Despite significant expression level in cancer cells, the role of the angiotensin II Type 2 receptor (AT2R) in cancer progression remains poorly understood.
  • We aimed to investigate the involvement of AT2R in tumorigenesis, hypothesizing a role in tumor cell proliferation and/or tumor angiogenesis.
  • Two animal tumor models were used: fibrosarcoma induced by 3-methylcholanthrene (3-MCA) in FVB/N mice invalidated for AT2R (AT2R-KO) and carcinoma LL/2 cells injected in C57BL/6N mice treated with AT2R antagonist PD123,319.
  • Tumor growth was monitored, microvascular density (MVD) evaluated by CD31 staining.
  • Proliferation index of LL/2 and 3-MCA tumor cells was evaluated by expression of Ki-67.
  • Angiogenesis was assessed by aorta ring assay and angiogenic mediators' expression by real-time RT-PCR.
  • Tumor induction by 3-MCA was significantly delayed in AT2R-KO compared to wild-type mice (56 days vs. 28 days).
  • In vitro, inactivation or invalidation of AT2R inhibited proliferation of LL/2 and 3-MCA tumor cells, respectively.
  • Tumor MVD was reduced in mice treated early with PD123,319.
  • Ex vivo experiments revealed a significant decrease in angiogenesis after PD123,319 treatment or in AT2R-KO mice.
  • Finally, we identified vascular endothelial growth factor (VEGF) as a soluble proangiogenic factor produced by LL/2 cells and we showed that in LL/2 and 3-MCA tumor cells, inhibition or deficiency of AT2R was associated with impaired production of proangiogenic factors included VEGF.
  • This study uncovered novel mechanisms by which AT2R would promote tumor development, favoring both malignant cell proliferation and tumor angiogenesis.
  • [MeSH-major] Angiotensin II Type 2 Receptor Blockers. Carcinoma, Lewis Lung / blood supply. Carcinoma, Lewis Lung / metabolism. Fibrosarcoma / blood supply. Fibrosarcoma / metabolism. Receptor, Angiotensin, Type 2 / deficiency
  • [MeSH-minor] Animals. Cell Growth Processes / drug effects. Cell Growth Processes / physiology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Female. Gene Deletion. Imidazoles / pharmacology. Methylcholanthrene. Mice. Mice, Inbred C57BL. Mice, Knockout. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / pathology. Pyridines / pharmacology. Reverse Transcriptase Polymerase Chain Reaction

  • Hazardous Substances Data Bank. 3-Methylcholanthrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20143398.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin II Type 2 Receptor Blockers; 0 / Imidazoles; 0 / Pyridines; 0 / Receptor, Angiotensin, Type 2; 130663-39-7 / PD 123319; 56-49-5 / Methylcholanthrene
  •  go-up   go-down


5. Ghanem N, Riede U, Uhrmeister P, Weigang E, Altehoefer C: Epithelioid angiosarcoma of the aorta. Vasa; 2002 Nov;31(4):269-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid angiosarcoma of the aorta.
  • Primary malignant tumors of the aorta are extremely rare.
  • Review of the literature indicates that there are nearly 100 recorded cases of primary malignant tumors of the aorta.
  • The purpose of this article is to present an additional case of the primary malignant tumors of the aorta which initially has been misinterpretated as atherosclerosic disease.
  • This aortic tumor was of endothelial origin and immunohistochemical studies classified the tumor as an epithelioid angiosarcoma.
  • The treatment resulted in an abdominal aortic repair.
  • MRI of the spine revealed multifocal metastatic disease of the axial skeleton and a subsequent chemotherapy was performed.
  • [MeSH-major] Aorta, Thoracic. Aortic Diseases / diagnosis. Hemangiosarcoma / diagnosis. Vascular Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12510553.001).
  • [ISSN] 0301-1526
  • [Journal-full-title] VASA. Zeitschrift für Gefässkrankheiten
  • [ISO-abbreviation] VASA
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Koizumi Y, Hara A, Tomita M, Sakamoto K, Obata H, Shiomi T, Nakajo S, Hashimoto K: [A case of advanced gastric cancer attaining histological CR of paraaortic lymph node after TS-1/CDDP neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2003 Sep;30(9):1351-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer attaining histological CR of paraaortic lymph node after TS-1/CDDP neoadjuvant chemotherapy].
  • A 60-year-old male complaining of anemic symptoms went through examinations and was diagnosed with gastric cancer (cardia, type 3', cT2, cN3, cH0, cP0, cM0, cStage IV).
  • Poor prognosis was predicted, yet we tried neoadjuvant chemotherapy (NAC) expecting down staging of the tumor.
  • The tumor itself showed PR-MR to the chemotherapy, but all the lymph nodes were expected to attain PR from CT findings.
  • Macroscopically, the stomach seemed to be penetrated into serosa by the tumor, i.e., se invasion was suggested, yet histologically no cancerous cells were detected within mp and ss layer.
  • Definitely no malignant cells were detected throughout all the lymph node specimens (Grade 3).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aorta. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Gastrectomy. Gastric Mucosa / pathology. Humans. Lymphatic Metastasis. Male. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518420.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Baretti R, Schaumann B, Meyer R, Alfaouri D, Hetzer R: [Metastasizing malignant germ cell tumor of the testis with infiltration of the thoracic aorta--a case for metastasis surgery]. Dtsch Med Wochenschr; 2000 Sep 29;125(39):1164-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastasizing malignant germ cell tumor of the testis with infiltration of the thoracic aorta--a case for metastasis surgery].
  • [Transliterated title] Metastasierender maligner Keimzelltumor des Hodens mit Infiltration der Aorta thoracica--Kasuistik zur Metastasenchirurgie.
  • Five years later the first mediastinal metastases were treated with high-dosage chemotherapy and autologous germ-cell transplantation, and remaining paraaortic--mediastinal tumour tissue was resected.
  • A curing treatment seemed impossible, because the aortic wall had been invaded.
  • TREATMENT AND COURSE: Five months after re-thoracotomy the metastasis and the invaded aortic segment were resected, the latter replaced by a vascular prosthesis.
  • Histology indicated metastasis of a malignant teratoma of intermediate type.
  • CONCLUSION: Combined orchidectomy, lymphadenectomy, high-dosage chemotherapy with cisplatin and autologous germ-cell transplantation at present constitute the standard treatment of malignant testicular germ-cell tumour.
  • In case of metastatic infiltration of vital structures, such as the aortic wall, special operative procedures can prolong the period of remission when the success of a standard treatment seems limited.
  • [MeSH-major] Aorta, Thoracic / surgery. Teratocarcinoma / secondary. Teratocarcinoma / surgery. Testicular Neoplasms / pathology. Vascular Neoplasms / secondary. Vascular Neoplasms / surgery
  • [MeSH-minor] Adult. Aortic Diseases / radiography. Aortic Diseases / surgery. Blood Vessel Prosthesis. Chemotherapy, Adjuvant. Humans. Lymph Node Excision. Male. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / surgery. Orchiectomy. Retroperitoneal Space. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11075244.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


8. Nagata M, Takayama T, Nishijima N, Mugiya S, Ushiyama T, Ozono S: [Clinical course of patient with malignant pheochromocytoma who was treated with CVD chemotherapy and alpha-methyl-p-tyrosine]. Nihon Hinyokika Gakkai Zasshi; 2010 May;101(4):615-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical course of patient with malignant pheochromocytoma who was treated with CVD chemotherapy and alpha-methyl-p-tyrosine].
  • The CT scan and bone scintigraphy showed right adrenal tumor, along with liver metastasis, lymph nodes swelling around aorta and multiple bone metastases.
  • She underwent chemotherapy consisting with Cyclophosphamide, Vincristine, Dacarbazine (CVD) and alpha-methyl-p-tyrosine (alphaMT), resulting in stable disease for 27 months.
  • We would have planned 131I-MIBG therapy, but bone marrow suppression did not allow us to do it.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Enzyme Inhibitors / administration & dosage. Pheochromocytoma / drug therapy. alpha-Methyltyrosine / administration & dosage

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20535990.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 5J49Q6B70F / Vincristine; 658-48-0 / alpha-Methyltyrosine; 7GR28W0FJI / Dacarbazine; 8N3DW7272P / Cyclophosphamide; CVD protocol
  •  go-up   go-down


9. Wang X, Tangjitgamol S, Liu J, Kavanagh JJ: Response of recurrent uterine high-grade malignant mixed müllerian tumor to letrozole. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1243-8
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of recurrent uterine high-grade malignant mixed müllerian tumor to letrozole.
  • Uterine malignant mixed müllerian tumor (MMMT) is a rare malignancy occurring most often in postmenopausal women.
  • Despite the use of multimodality treatments including surgery, chemotherapy, and radiotherapy, prognosis is still poor in most cases.
  • Two years later, an asymptomatic retroperitoneal mass was discovered on surveillance abdominal computed tomography scanning.
  • The 3.5- x 3.0-cm mass was considered inoperable owing to its location near the aorta at the level of the renal vessels.
  • The patient declined radiation or chemotherapy.
  • Treatment with letrozole was begun at 2.5 mg daily.
  • Serial computed tomography scans demonstrated marked tumor shrinkage; after 11 months of letrozole therapy, the tumor had shrunk to less than 25% of its original volume.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Mixed Tumor, Mullerian / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343224.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


10. Suzuki Y, Tokuda Y, Okumura A, Saito Y, Ohta M, Kubota M, Makuuchi H, Tajima T, Umemura S, Osamura RY: Three cases of malignant lymphoma of the breast. Jpn J Clin Oncol; 2000 Jan;30(1):33-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of malignant lymphoma of the breast.
  • We report three cases of malignant lymphoma (ML) of the breast and discuss diagnosis and management.
  • The first case is a 35-year-old woman who had a left breast tumor.
  • Mastectomy was performed without any adjuvant chemotherapy.
  • Seventy one months after surgery, lesions indicating relapse were detected in nodes of the right axilla, mediastinum and para-aorta.
  • She underwent eight cycles of CHOP regimen, but 1 month after the chemotherapy a brain metastasis was detected.
  • Histology of the tumor revealed diffuse large B-cell lymphoma.
  • The patient underwent eight cycles of CHOP regimen and high-dose chemotherapy (HDC) with peripheral blood stem cell transplantation (PBSCT).
  • The third case is a 38-year-old woman who had a right breast tumor.
  • FNAC of the breast tumor showed ML and a CT scan of the chest revealed lymphadenopathy at the crus of the diaphragm.
  • Histology of the tumor revealed low-grade B-cell lymphoma of MALT type.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Brain Neoplasms / secondary. Chemotherapy, Adjuvant. Cranial Irradiation. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Lymphatic Metastasis / pathology. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Mastectomy, Extended Radical. Middle Aged. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10770567.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


11. Murakami S, Terakado M, Misumi M, Tsuji Y, Okubo K, Hirayama R, Inoue K, Arai E: Situs inversus totalis with malignant lymphoma of the stomach: report of a case. Surg Today; 2003;33(7):533-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Situs inversus totalis with malignant lymphoma of the stomach: report of a case.
  • We report a case of situs inversus totalis with malignant lymphoma of the stomach, which was successfully treated by surgery followed by chemotherapy and irradiation.
  • Chest X-ray showed a right-sided heart, and ultrasonography and computed tomography (CT) of the abdomen showed a situs inversus totalis with multiple gallstones in the gallbladder.
  • Tree-dimensional reconstructed CT of the abdomen showed no other malformations coexisting with situs inversus totalis, but a barium upper gastrointestinal series found an inverted stomach and an elevated tumor with ulceration in the center, localized in the antrum of the stomach.
  • Histopathological examination confirmed a diagnosis of malignant lymphoma of the stomach (diffuse large B-cell type) with metastasis to the regional lymph nodes.
  • Chemotherapy using the CHOP regimen was given three times, starting 1 month postoperatively.
  • A followup CT scan showed enlargement of one lymph node around the abdominal aorta and irradiation was delivered to the area of the inverted Y in the abdomen.
  • At the time of writing, 10 months after surgery, the patient is well with no signs of recurrence and leading a normal life.
  • Careful preoperative assessment is very important for determining the most appropriate surgical procedure in patients with situs inversus totalis associated with a malignancy.
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Imaging, Three-Dimensional. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Situs inversus.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14507000.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Corsini E, Gelati M, Calatozzolo C, Alessandri G, Frigerio S, De Francesco M, Poiesi C, Parati E, Croci D, Boiardi A, Salmaggi A: Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization. Cancer Immunol Immunother; 2004 Nov;53(11):955-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization.
  • Conventional antitumoral treatments (i.e., surgery, radiotherapy, and chemotherapy) do not achieve satisfactory results (median survival in glioblastoma 12-18 months).
  • It has been suggested that immunotherapy with xenogenic endothelial cells could slow tumor growth rate in a number of tumors in a murine model, but the study did not include gliomas.
  • In experiments performed in our laboratory, vaccination with proliferating bovine aortic endothelium increased survival time in Fischer rats inoculated intracerebrally with 9L.
  • Immunoglobulins (Ig) in the sera from vaccinated rats stained bovine aortic endothelium as well as human umbilical vein endothelium in active proliferation.
  • Moreover, immune sera from immunized rats stained microvessels of human malignant glioma specimens and vessels of intracerebrally implanted tumors.
  • [MeSH-major] Aorta / cytology. Brain Neoplasms / therapy. Endothelial Cells / cytology. Endothelium, Vascular / cytology. Glioma / therapy. Immunotherapy / methods. Skin Neoplasms / therapy
  • [MeSH-minor] Animals. Blotting, Western. Brain / metabolism. Cattle. Cell Division. Cell Line, Tumor. Cells, Cultured. Humans. Immunoglobulin G / blood. Immunoglobulin G / chemistry. Immunoglobulins / chemistry. Injections, Subcutaneous. Interferon-gamma / metabolism. Microcirculation. Neoplasms / pathology. Neovascularization, Pathologic. Rats. Rats, Inbred F344. Time Factors. Tumor Necrosis Factor-alpha / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15449042.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunoglobulins; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


13. Oechsle K, Aebert H, Teichmann R, Budach W, Kanz L, Ziemer G, Hartmann JT: Primary malignant sarcomas of the heart and great vessels - a single center experience. J Clin Oncol; 2004 Jul 15;22(14_suppl):9044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant sarcomas of the heart and great vessels - a single center experience.
  • All pts were symptomatic with reduction of vitality, anorexia, dyspnoea, or neurological symptoms at the time of reception.
  • Tumors were located in atrium [(n=5), left (3)/right (2)], Art. pulmonalis (n=3), Aorta (n=2), pericardium or left chamber, (n=1 each).
  • Five of these 6 pts underwent palliative resection to relieve the physiologic effects of the tumor.
  • Three out of 5 pts with curative intended surgery have subsequently developed recurrence within 6, 8 and 25 mos despite adjuvant treatment.
  • Palliative chemotherapy including adriamycin and ifosfamide has been applied in 7 pts and 4 pts attained some response to treatment (n=1 PR, n=3 SD).
  • Palliative radiation included 3 pts with brain metastases and a single pt with progressive primary tumor.
  • After a median follow up 13 mos (2 -28) 2 pts had NED, 3 pts are alive with disease and 7 pts have died due to tumor progression.
  • These pts should preferentially be referred to a tertiary Cancer Center immediately after diagnosis without preceding treatment attempts.
  • Although the majority of pts cannot be treated curatively due to the delay in diagnosis, an optimized treatment approach including neoadjuvant chemo-/radiotherapy might enhanced the rate of complete resection depending on the histological subtype and responsiveness to treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013704.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Chrysos E, Tsiaoussis J, Alexandra K, Athanasakis H, Tsetis D, Varveris C, Fiorentini G, Lucchi SR, Vassilakis JS, Zoras O: Treatment of unresectable malignant abdominal, pelvic and thoracic tumors using abdominal pelvic and thoracic stop-flow chemotherapy. Anticancer Res; 2001 Sep-Oct;21(5):3669-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of unresectable malignant abdominal, pelvic and thoracic tumors using abdominal pelvic and thoracic stop-flow chemotherapy.
  • BACKGROUND: Stop-flow perfusion (SFP) has been recently used to enhance the effects of chemotherapy in patients with locally advanced tumors.
  • PATIENTS AND METHODS: Over a 2-year period we performed abdominal, pelvic and thoracic SFP in 12 patients with unresectable or metastatic tumors, using balloon catheters inserted into the abdominal aorta and inferior vena cava.
  • The chemotherapeutic agents were directly administered into the aorta and/or inferior vena cava for thoracic SFP.
  • The procedure was repeated in each patient, with one-month interval between sessions.
  • RESULTS: At post-operative CT or MRI follow-up, tumor shrinkage of more than 50% was observed in six patients, while post-SFP chemotherapy surgical resection of the tumors became feasible in four cases.
  • Post-operative recovery was uneventful in all but two patients, who developed minor systemic toxicity.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Pelvic Neoplasms / drug therapy. Thoracic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Chemotherapy, Cancer, Regional Perfusion / methods. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11848541.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Sugarbaker DJ, Wolf AS: Surgery for malignant pleural mesothelioma. Expert Rev Respir Med; 2010 Jun;4(3):363-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for malignant pleural mesothelioma.
  • The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological understanding of this rare and aggressive malignancy.
  • In the multimodality treatment paradigm, the goal of surgery is to provide a macroscopic complete resection (i.e., complete removal of all grossly visible tumor).
  • The former is indicated for patients with advanced locally invasive disease; the latter for patients with more superficial spread of tumor that spares the lung and fissures.
  • If critical mediastinal structures (e.g., aorta and vertebral bodies) are found to be involved at thoracotomy, the tumor is classified as T4, and pleurectomy/decortication is recommended.
  • Despite having more advanced disease, a subset of patients with favorable prognostic factors can experience extended survival by undergoing trimodality therapy with extrapleural pneumonectomy, chemotherapy and/or radiation.
  • Much of what we know about the biology of mesothelioma has been gleaned from studying the surgical pathophysiology, including the delineation of histopathologic subtypes, disease stage stratification with survival, the propensity for local (in contrast to systemic) recurrence, as well as the prognostic effect of epithelial versus nonepithelial cell type, extrapleural nodal involvement, tumor bulk and surgical margins.
  • Pending the discovery of new drugs, the focus of clinical research over the next 5 years will emphasize refinements in patient selection, pathologic staging, molecular staging and other novel adjuvant therapies.
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant. Thoracotomy. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524919.001).
  • [ISSN] 1747-6356
  • [Journal-full-title] Expert review of respiratory medicine
  • [ISO-abbreviation] Expert Rev Respir Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 70
  •  go-up   go-down


16. Yoshioka M, Mori T, Okuma T, Kitamura N, Ito N, Nishi K: Mediastinal growing teratoma syndrome. Jpn J Thorac Cardiovasc Surg; 2000 Jan;48(1):66-8
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 27-year-old man had undergone orchiectomy and chemotherapy for testicular cancer.
  • Despite normalization of raised tumor marker levels after postoperative chemotherapy, computed tomographic scanning demonstrated multiple swellings of the para-aortic lymph nodes with extension from beneath the aortic arch to the bifurcation of the descending aorta.
  • Open biopsies of the para-aortic lymph nodes disclosed mature teraroma without malignant cells.
  • Histological examination of the resected specimens revealed a mature teratoma component without malignant cells.
  • [MeSH-minor] Adult. Follow-Up Studies. Germinoma / drug therapy. Germinoma / surgery. Humans. Male. Orchiectomy. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / surgery. Syndrome. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10714023.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


17. Umscheid TW, Rouhani G, Morlang T, Lorey T, Klein PJ, Ziegler P, Stelter WJ: Hemangiosarcoma after endovascular aortic aneurysm repair. J Endovasc Ther; 2007 Feb;14(1):101-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiosarcoma after endovascular aortic aneurysm repair.
  • CASE REPORT: A 50-year-old man with Klinefelter syndrome presented 5 years after EVAR with a mass at the infrarenal aorta outside the stent-graft.
  • The stent-graft with the surrounding aorta was removed and replaced by a conventional tube graft.
  • Systemic chemotherapy followed.
  • The tumor recurred after 12 months, with pulmonary metastases and tumor embolic occlusion of his left femoral artery.
  • Thrombectomy was performed, and a second course of chemotherapy was administered.
  • The patient died 24 months after the conversion procedure.
  • CONCLUSION: Morphological changes of the aneurysm wall seen on computed tomographic scans of EVAR patients may not be incidental or signs of infection; rather, a malignant tumor of the aorta or lymphatic disease, although rare, have to be taken into consideration as well.
  • [MeSH-major] Aortic Aneurysm, Abdominal / surgery. Blood Vessel Prosthesis Implantation / adverse effects. Hemangiosarcoma / etiology. Stents
  • [MeSH-minor] Fatal Outcome. Humans. Klinefelter Syndrome / complications. Male. Middle Aged. Polyethylene Terephthalates. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17291154.001).
  • [ISSN] 1526-6028
  • [Journal-full-title] Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
  • [ISO-abbreviation] J. Endovasc. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Polyethylene Terephthalates
  •  go-up   go-down


18. De Santis M, Ariosi P, Calò GF, Luppi G, Franchini M, Romagnoli R: [Antineoplastic perfusion with percutaneous stop-flow control in the treatment of advanced pelvic malignant neoplasms]. Radiol Med; 2000 Jul-Aug;100(1-2):56-61
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Antineoplastic perfusion with percutaneous stop-flow control in the treatment of advanced pelvic malignant neoplasms].
  • PURPOSE: The object of our study was to apply percutaneous stop-flow technique to advanced pelvic cancer in order to evaluate its feasibility, standardize the procedure and obtain preliminary results.
  • All treatments were performed under general anesthesia.
  • Blood flow was interrupted for a maximum of 20 min to limit tissue damage, especially of the anal sphincter.
  • Morphological response was evaluated by CT or MR scan performed prior to and 40 days after the treatment.
  • Death followed tumor progression in 6 cases; one patient died during the procedure and another one after 7 days, both secondary to pulmonary embolism.
  • Complications included intra-arterial rupture of the balloon in one case and a large inguinal hematoma 10 days after the treatment, requiring hospitalization.
  • CONCLUSIONS: This trial supports the feasibility of using the percutaneous stop-flow procedure in an angiography room setting; the stop-flow technique failed to permit the effective control of the tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Neoplasm Recurrence, Local / drug therapy. Pelvic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Anesthesia, General. Antibiotics, Antineoplastic / administration & dosage. Aorta, Abdominal / radiography. Cisplatin / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Mitomycin / administration & dosage. Pelvis / pathology. Pelvis / radiography. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109453.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Chauty A, Raimondo G, Vergeron H, Branchereau S, Dessemme P, Devictor D, Hartmann O: [Discovery of a neuroblastoma producing cardiogenic shock in a 2-month-old child]. Arch Pediatr; 2002 Jun;9(6):602-5
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A two-month-old male child presented a severe heart failure associated with a malignant hypertension.
  • CT scan showed a tumor of 7 x 6 x 8 cm, forcing back both the left kidney and the aorta.
  • Under chemotherapy the tumor volume decreased significantly and complete surgical excision became possible.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / diagnosis. Hypertension, Malignant / etiology. Neuroblastoma / complications. Neuroblastoma / diagnosis. Shock, Cardiogenic / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Catecholamines / secretion. Diagnosis, Differential. Hemodynamics. Humans. Infant. Male

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma 2.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12108315.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Catecholamines
  •  go-up   go-down


20. Seki H, Shiina M: Placement of a long tapered side-hole catheter in the hepatic artery: technical advantages, catheter stability, and arterial patency. AJR Am J Roentgenol; 2006 Nov;187(5):1312-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The purpose of this study was to evaluate the technical advantages, safety, and efficacy of placing a catheter distally in the hepatic artery using a long tapered side-hole catheter with an implantable port for hepatic arterial infusion chemotherapy.
  • SUBJECTS AND METHODS: Fifty patients with unresectable malignant liver tumors underwent radiologic implantation of catheter-port systems using the long tapered catheter placement method.
  • A 2.7-French distal shaft of the catheter was inserted distally in the hepatic artery with its side hole located proximally, and a 5-French proximal shaft was placed in the aorta; the catheter tip was not fixed.
  • Technical success, complications including catheter stability and hepatic artery patency, and tumor response were assessed and compared with the following two historical controls: 35 patients with a 5-French catheter inserted simply in the hepatic artery (conventional method), and 131 patients with a 5-French catheter, the tip of which was fixed in the gastroduodenal artery (the fixed-catheter-tip method).
  • The time of hepatic tumor progression was significantly longer using the long tapered catheter placement method than using the conventional method (p = 0.0299) but was comparable to the time using the fixed-catheter-tip method.
  • CONCLUSION: The long tapered catheter placement method should find wider application in hepatic arterial infusion chemotherapy because it is useful in preventing catheter dislodgment and hepatic artery occlusion.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Female. Humans. Infusions, Intra-Arterial. Liver Neoplasms / drug therapy. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056922.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Kawaguchi M, Asada Y, Terada T, Takehara A, Munemoto Y, Fujisawa K, Mitsui T, Iida Y, Miura S, Sudo Y: Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor. Int J Clin Oncol; 2010 Apr;15(2):191-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor.
  • Gastroendoscopy and gastrography demonstrated a type-2 tumor in the upper region of the stomach.
  • CT scan and fluorodeoxyglucose-positron emission tomography (FDG-PET) scan demonstrated gastric cancer and its metastatic lymph nodes.
  • Although postoperative adjuvant chemotherapy by S-1 was started, the deteriorating condition of the patient prevented drug administration and even eating meals.
  • On the 19th postoperative day (POD), FDG-PET scan of the body demonstrated new uptake in the liver and lymph node around the aorta.
  • Without any sign of infection, leukocytosis developed around the 30th POD.
  • G-CSF-producing tumor is a rare but aggressive disease, particularly as recurrent tumor.
  • If leukocytosis is detected in relation to a non-lympho hematopoietic malignant tumor, G-CSF-producing tumor should be considered and FDG-PET scan is recommended for early detection.
  • Chemotherapy for G-CSF-producing tumor must be conducted as soon as possible.
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Drug Combinations. Fatal Outcome. Fluorodeoxyglucose F18. Gastroscopy. Humans. Leukocytosis / etiology. Leukocytosis / metabolism. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Oxonic Acid / therapeutic use. Positron-Emission Tomography. Radiopharmaceuticals. Splenectomy. Tegafur / therapeutic use. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2005;8(3):173-7 [16086120.001]
  • [Cites] Histol Histopathol. 2002 Oct;17 (4):1005-16 [12371127.001]
  • [Cites] Ann Nucl Med. 2008 Aug;22(7):635-9 [18756367.001]
  • [Cites] Surg Today. 2008;38(5):453-7 [18560971.001]
  • [Cites] Jpn J Clin Oncol. 2007 Oct;37(10):793-6 [17720735.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Ann Pharmacother. 2002 Nov;36(11):1796-9 [12398579.001]
  • [Cites] Gastric Cancer. 2005;8(3):198-201 [16086124.001]
  • [Cites] Ann N Y Acad Sci. 1974;230:212-8 [4522870.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):782-8 [3874682.001]
  • (PMID = 20179985.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  • [Number-of-references] 15
  •  go-up   go-down


22. Tsuji Y, Matsuda H, Hara I, Yoshimura M, Okita Y: Aortic and vena caval reconstruction with retroperitoneal lymph node dissection for metastatic germ cell tumor. Vasa; 2005 May;34(2):140-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aortic and vena caval reconstruction with retroperitoneal lymph node dissection for metastatic germ cell tumor.
  • A 49-year-old man who had a huge testicular tumor with retroperitoneal lymph node metastasis and bilateral multiple pulmonary metastases was referred to our hospital.
  • Firstly orchiectomy was done obtaining the pathological diagnosis of mixed type germ cell tumor.
  • After cisplatin-based chemotherapy, he underwent resection of the retroperitoneal lymph node involving the abdominal aorta and the inferior vena cava.
  • Both great vessels were resected with the tumor and reconstructed with prosthetic grafts.
  • Microscopically, all resected metastatic tumors were diagnosed to be mature teratoma without viable malignant cells.
  • Follow-up CT scan demonstrates patency of aortic and vena caval bypass grafts without local recurrence or distant metastasis.
  • [MeSH-major] Aorta / surgery. Lymph Nodes / surgery. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Germ Cell and Embryonal / therapy. Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy. Venae Cavae / surgery
  • [MeSH-minor] Humans. Lymphatic Metastasis. Male. Middle Aged. Peritoneum / pathology. Peritoneum / radiography. Peritoneum / surgery. Reconstructive Surgical Procedures / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968899.001).
  • [ISSN] 0301-1526
  • [Journal-full-title] VASA. Zeitschrift für Gefässkrankheiten
  • [ISO-abbreviation] VASA
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Hagiuda J, Matsumoto M, Hanawa Y, Ishikawa H, Marumo K: [Adenocarcinoma of the rete testis. A case report]. Nihon Hinyokika Gakkai Zasshi; 2010 Nov;101(7):749-53
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenocarcinoma of the rete testis is a rare malignant tumor with a poor prognosis.
  • Positron emission tomography (PET) was performed in another hospital, and the patient was referred for a left testicular tumor, multiple lung metastases, and para-aorta lymph node metastasis.
  • Pathological examination revealed a hard whitish mass around the testis involving the epididymis and tunica vaginalis and spreading under the subcutaneous tissue.
  • Histological examination revealed adenocarcinoma in the hilum of the testis, which extended to the subcutaneous tissue but not to the surface of the scrotum.
  • After the histological diagnosis of adenocarcinoma of the rete testis was confirmed, computed tomography (CT) was performed and showed multiple pulmonary nodules and para-aortica lymph node swelling of 3 cm diameter.
  • Because the patient did not wish to receive chemotherapy or other aggressive treatment, he has been followed-up with palliative care since his diagnosis.
  • [MeSH-major] Adenocarcinoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Aged, 80 and over. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Orchiectomy. Palliative Care. Positron-Emission Tomography. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21174741.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Voronov E, Reich E, Dotan S, Dransh P, Cohen I, Huszar M, Fogel M, Kleinman HK, White RM, Apte RN: Effects of IL-1 molecules on growth patterns of 3-MCA-induced cell lines: an interplay between immunogenicity and invasive potential. J Immunotoxicol; 2010 Mar;7(1):27-38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The balance between inflammation and immunity is cardinal for the outcome of the malignant process.
  • Local attenuated inflammatory responses mediated by innate cells may provide accessory signals for the development of acquired immunity against malignant cells.
  • In contrast, excessive inflammatory responses accompany tumorigenesis and tumor invasiveness, by the induction of immunosuppression.
  • In the present study, we have assessed the role of tumor cell-derived IL-1 in determining the invasive versus immunostimulatory potential of tumor cells.
  • We could not detect differences in cell surface markers related to immunogenicity, such as MHC Class I, co-stimulatory, or adhesion molecules between both types of cells.
  • However, more T-cells were observed at the inoculation site of tumor cells devoid of IL-1 and more pronounced parameters related to anti-tumor immunity were observed in the spleen (IL-12 and IFNgamma) of these mice, compared to mice bearing tumors derived from control mice, where host-derived IL-1 is present.
  • In addition, injection of tumor cells devoid of IL-1, which failed to grow in mice, induced an anti-tumor cell immune memory, while in mice injected with tumor cells from control mice; no immune memory could be detected.
  • From the results, it seems that IL-1 is a crucial factor in determining the balance between immunity and inflammation in tumor-bearing mice.
  • This suggests that manipulation of IL-1 could be useful in anti-tumor therapy, by reducing invasiveness and promoting immunity against the malignant cells.
  • [MeSH-major] Fibrosarcoma / immunology. Interleukin-1 / immunology. Neoplasm Invasiveness / immunology. Neoplasm Transplantation / immunology. Sarcoma, Experimental / immunology
  • [MeSH-minor] Animals. Aorta, Thoracic / drug effects. Cell Line, Tumor. Chick Embryo. Culture Media, Conditioned / pharmacology. Cytokines / metabolism. Endothelial Cells / drug effects. Female. Methylcholanthrene / pharmacology. Mice. Mice, Inbred C57BL. Mice, Knockout. Neovascularization, Pathologic / immunology. Spleen / drug effects. Spleen / metabolism. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. 3-Methylcholanthrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001788.001).
  • [ISSN] 1547-6901
  • [Journal-full-title] Journal of immunotoxicology
  • [ISO-abbreviation] J Immunotoxicol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Cytokines; 0 / Interleukin-1; 56-49-5 / Methylcholanthrene
  •  go-up   go-down


25. Hanaoka N, Nagao H, Murakami T, Chijiwa T, Suganuma T: [A case of follicular lymphoma with onset of chylothorax]. Nihon Kokyuki Gakkai Zasshi; 2007 Jan;45(1):31-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chest X-rays showed bilateral pleural effusion, and an abdominal CT scan revealed a large intraperitoneal tumor around the abdominal aorta and pancreas.
  • Cases of malignant lymphoma with chylothorax are rarely reported in Japan, but should be taken into account when examining cases of non-traumatic chylothorax.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chylothorax / etiology. Lymphoma, Follicular / complications. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313024.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


26. Vogl TJ, Zangos S, Eichler K, Balzer JO, Jacob U, Keilhauer R, Bauer RW: [Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases]. Rofo; 2007 Nov;179(11):1174-80
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Transarterielle Chemoperfusion des Beckens--Ergebnisse bei symptomatischen Rezidivtumoren und Lymphknotenmetastasen.
  • PURPOSE: To evaluate local transarterial chemoperfusion (TACP) of therapy-resistant, locally recurrent malignant tumors and lymph node metastases in the pelvis with respect to clinical response, tumor response and survival.
  • Depending on the tumor location and vascularization, a fluoroscopy catheter was placed either in the abdominal aorta or internal pelvic artery.
  • The tumor size was measured using CT or MRI.
  • In the case of clinical and radiological progression, therapy was stopped and the patient was referred to the hospital's tumor board.
  • In the case of radiological response and clinical progression or clinical response and radiological progression, therapy was continued.
  • Therapy could be stopped by the patient at any time.
  • RESULTS: Treatment was tolerated well by all patients.
  • Tumor-related pain, bleeding, restricted mobility of the lower extremities, incontinence, urinary tract obstruction, and constipation were reduced in 9/17, 5/6, 3/3, 1/3, 2/5, and 1/3 of cases (clinical response rate: 54%).
  • Radiologically, 4/24 (17%) patients showed PR, 12/24 (50%) SD, and 8/24 (34%) PD (tumor control (PR+SD): 67% of cases).
  • Tumor response (median survival since first TACP) was as follows: colorectal: 2 PR, 7 SD, 2 PD (11.5 months), ovarian: 1 SD, 2 PD (8.5 mon), cervical: 1 PR, 1 SD (6 mon), breast: 2 SD (6 mon), gastric: 1 PD (11 mon), adrenal gland: 1 PD (12 mon), anal: 1 PD (10 mon), prostate: 1 PD (20 mon), Gartner's duct: 1 PR (20 mon), renal cell carcinoma: 1 SD (10 mon).
  • CONCLUSION: Since tumor-related complaints were improved in 54% of the cases and control of tumor growth (PR+SD) was achieved in 67% of the cases, TACP for recurrent pelvic malignancies should be considered as a palliative oncological treatment option.
  • [MeSH-major] Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Arteries. Drug Resistance, Neoplasm. Female. Humans. Injections, Intra-Arterial / adverse effects. Middle Aged. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Perfusion / adverse effects. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805998.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin
  •  go-up   go-down


27. Kim YH, Shin EK, Kim DH, Lee HH, Park JH, Kim JK: Antiangiogenic effect of licochalcone A. Biochem Pharmacol; 2010 Oct 15;80(8):1152-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To date, no antiangiogenic activity has been demonstrated for licochalcone A (LicA), a major phenolic constituent of Glycyrrhiza inflata, although it shows significant antitumor activity in human malignant cell lines.
  • LicA significantly inhibited proliferation (20 microM), migration (5-20 microM), and tube formation (10-20 microM) of human umbilical vascular endothelial cells (HUVECs) as well as microvessel growth from rat aortic rings (10-20 microM).
  • Inhibition of tumor growth may be attributed, at least in part, to decreased angiogenesis in LicA-treated mice.
  • These findings emphasize the potential use of LicA against tumor development and progression in which angiogenesis is stimulated.
  • [MeSH-major] Chalcones / pharmacology. Neovascularization, Pathologic / drug therapy
  • [MeSH-minor] Animals. Aorta / drug effects. Colonic Neoplasms / blood supply. Colonic Neoplasms / drug therapy. Endothelial Cells / drug effects. Glycyrrhiza / chemistry. Humans. Male. Mice. Mice, Inbred BALB C. Molecular Structure. Neoplasms, Experimental / drug therapy. RNA Interference. Rats. Signal Transduction. Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20637733.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chalcones; 58749-22-7 / licochalcone A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


28. Nord C, Fosså SD, Giercksky KE: Gastrointestinal presentation of germ cell malignancy. Eur Urol; 2000 Dec;38(6):721-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In 4 patients the duodenum and in 1 patient the distal part of the esophagus were involved in germ cell malignancy.
  • Ulceration of the upper GI tract was in 1 case complicated by an aortoduodenal fistula with rupture of the aorta.
  • This patient and 2 other cases needed emergency surgery due to GI hemorrhage before and/or during the initial phase of chemotherapy.
  • Our observations compare well with the literature, showing the need of multimodality therapy of these complications.
  • CONCLUSION: In young males with a malignant tumor in the upper GI tract, the diagnosis of germ cell malignancy should be considered.
  • Treatment of this condition requires a multimodality approach, not rarely including emergency surgery.
  • Though these patients often belong to a poor-prognosis group, our results and the literature review show that long-term survival is possible using modern treatment principles.
  • In particular, the risk of GI hemorrhage, during the initial phase of therapy, should not be overseen.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11111190.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] SWITZERLAND
  • [Number-of-references] 10
  •  go-up   go-down


29. Halperin EC: Neonatal neoplasms. Int J Radiat Oncol Biol Phys; 2000 Apr 1;47(1):171-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To describe neoplasms diagnosed in children </= 28 days of age along with their treatment, associated congenital anomalies, and the long-term consequences of the diagnoses and treatments.
  • METHODS AND MATERIALS: Utilizing autopsy records, a computerized tumor registry, and medical records, we identified patients and stillborns at Duke University Medical Center (DUMC) diagnosed with neoplasms at </= 28 days of age between 1930 and 1998.
  • The 20 patients identified via the computerized registry system for 1980-1998 constitute 2% (20/925) of all neoplasms seen in patients </= 16 years of age over this same time period at DUMC.
  • The histologic diagnoses were teratoma/germ cell tumor (n = 8, 35%), neuroblastoma (n = 5, 22%), retinoblastoma (n = 4, 17%), primary central nervous system (CNS) tumor (n = 3, 13%), and one case each of rhabdomyosarcoma, glossal glial choristoma, and hemangioma in the setting of Kasabach-Merritt Syndrome.
  • Of the eight teratoma/germ cell tumor patients, 6 were female (75%) and 2 male (25%).
  • There was one malignant germ cell tumor, 2 immature teratomas, and 5 teratomas.
  • The one patient with malignant germ cell tumor, treated with surgery and chemotherapy, died.
  • Associated anomalies were imperforate anus, congenital absence of a limb, left ventricular hypertrophy, fusion or absence of toes, coarctation of the aorta, and pulmonary valve dysplasia.
  • Two were treated with surgery + chemotherapy + radiotherapy; two with surgery + chemotherapy; and one with surgery alone.
  • A child with a dumbbell neuroblastoma, treated with surgery and chemotherapy, is paraplegic.
  • The two children with trilateral retinoblastoma died after therapy with surgery, craniospinal and orbital irradiation, and chemotherapy.
  • Two children with bilateral disease are long-term survivors: one treated with radiotherapy + chemotherapy and one with radiotherapy alone.
  • The histologies were glioblastoma multiforme, anaplastic astrocytoma, and malignant mixed oligodendroglioma.
  • Two of the patients are long-term survivors after surgery + chemotherapy.
  • Six children received eight courses of radiation therapy: 2 for Stage 4S neuroblastoma with respiratory compromise from an enlarging liver and 4 for retinoblastoma.
  • The two infants with trilateral retinoblastoma received two courses of irradiation each: one of the treatment of intraocular tumor and a second, at an older age, for the pineal tumor.
  • CONCLUSION: The most common neonatal neoplasm histologic diagnoses are teratoma/germ cell tumor, neuroblastoma, and retinoblastoma.
  • Radiation therapy is administered infrequently in a population highly susceptible to late ill effects.
  • When radiotherapy is required, anesthesia may be repetitively administered to aid in reproducible treatment.
  • [MeSH-minor] Anesthesia. Brain Neoplasms / epidemiology. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Female. Follow-Up Studies. Hemangioma / epidemiology. Hemangioma / pathology. Hemangioma / therapy. Humans. Infant, Newborn. Male. Neuroblastoma / epidemiology. Neuroblastoma / pathology. Neuroblastoma / therapy. Registries. Retinoblastoma / epidemiology. Retinoblastoma / pathology. Retinoblastoma / therapy. Survivors. Teratoma / epidemiology. Teratoma / pathology. Teratoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10758320.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


30. Marcinkowska A, Malarska A, Saczko J, Chwiłkowska A, Wysocka T, Drag-Zalesińska M, Wysocka T, Banaś T: Photofrin--factor of photodynamic therapy induces apoptosis and necrosis. Folia Histochem Cytobiol; 2001;39 Suppl 2:177-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photofrin--factor of photodynamic therapy induces apoptosis and necrosis.
  • Photodynamic therapy (PDT) causes irreversible photodamage of tumor and other malignant tissues.
  • The studies were performed on endothelial cell line from foetal aorta of calves and on normal fibroblasts cell line (3T3 -Balb) and also on malignant line (A431).
  • The cells were grown in presence of photofrin at different time intervals.
  • Time of interaction of photosensitiser with cells was very important.
  • Short time of exposure of the cells to photofrin induced mostly apoptosis in normal cells and apoptotic or necrotic changes in malignant cells.
  • These results strongly suggest that HpD has an effect on generation of ROS, which are a signal for development of morphological changes (apoptosis or necrosis) in normal and malignant cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11820595.001).
  • [ISSN] 0239-8508
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Reactive Oxygen Species; 97067-70-4 / Dihematoporphyrin Ether; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


31. Kecmanović D, Kovacević P, Pavlov M, Sepetkovski A, Ceranić M: [Cytoreductive procedures in advanced primary ovarian carcinoma]. Acta Chir Iugosl; 2001;48(1):71-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Explorative curretage of uterus--PH findings: malignant tissue.
  • Irigography: spasticity and extraluminal compression to proximal third of rectum and distal sigmoid colon.
  • Ultrasound of liver: without signs of malignant disease.
  • CT-scan of pelvis and abdomen: metastatic lymph nodes, up to 40 mm in diameter, alongside abdominal aorta; solid-lobular tumor, 10 x 7 cm, on the left side of urinary bladder, which fills the central portion of pelvic cavum.
  • Secundary malignant deposits on the pelvic parietal peritoneum with minimal quantity of ascites (peritoneal carcinomatosis).
  • Intraoperative findings confirmed malignant deposits on the right colon serosa, so we performed right hemicolectomy with ileo-colo anastomosis, omentectomy, hysterectomy, bilateral adnexectomy, low anterior resection of the rectum, peritonectomy of pelvis and reconstruction of digestive tubus by colo-rectal anastomosis with circular stapler ILS 33.
  • One month after the operation, systemic chemotherapy consisting of Endoxan and Karboblastin was administered, for the duration of 6 months, once monthly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11432258.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] hrv
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Yugoslavia
  •  go-up   go-down






Advertisement